| 英文別名： |
HOLO-TRANSFERRIN;HUMAN TRANSFERRIN;HUMAN TRASFERRIN;HUMAN SEROTRANSFERRIN;HUMAN APO-TRANSFERRIN;HUMAN HOLO-TRANSFERRIN;HOLO-TRANSFERRIN BOVINE;HOLO-TRANSFERRIN HUMAN;Transferrin;Transferrin, Human, recombinant expressed in plant s;apo-transferrin;apo-transferrin bovine;apo-transferrin guinea pig;apo-transferrin human cell culture*tested;apo-transferrin mouse;Human Holo Transferrin;transferrin bovine holo-form*iron-saturated cell;Transferrin human;Transferrin, Apo-, Bovine Plasma;Transferrin, Apo-, Human Plasma;Transferrin, Apo-, TC Grade, Pyrogen-Free, Human Plasma;Transferrin, Apo-, Tissue Culture Grade, Human Plasma;Transferrin, Holo, Human Plasma;TRF;Siderophilin, iron-saturated;Siderophilin, partially saturated;Holotransferrins;Muscle trophic factor;Optiferrin;SIDEROPHILIN;transferrins;TRANSFERRIN (APO);TRANSFERRIN (HOLO);Bovine Transferrin;L-Pyroglutamyl-L-histidinyl-L-prolinamide;L-Pyroglutamyl-L-histidinyl-L-prolinamide;AKOS015994636;AKOS015994636;5-oxo-pro-his-pro-nh2;5-oxo-pro-his-pro-nh2;BDBM50072394;BDBM50072394;TSH-RF;TSH-RF;AKOS040759052;AKOS040759052;2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-;2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-;Relefact TRH (TN);Relefact TRH (TN);PROTIRELIN [JAN];PROTIRELIN [JAN];NSC-760113;NSC-760113;Thyrefact;Thyrefact;Protirelin, synthetic;Protirelin, synthetic;CHEBI:35940;CHEBI:35940;Protirelina [INN-Spanish];Protirelina [INN-Spanish];Synthetic TRF;Synthetic TRF;L-Pyroglutamyl-L-histidyl-L-prolinamide;L-Pyroglutamyl-L-histidyl-L-prolinamide;PROTIRELIN [WHO-DD];PROTIRELIN [WHO-DD];Abbott 38579;Abbott 38579;Q24726011;Q24726011;Stimu-TSH;Stimu-TSH;protirelin;protirelin;(2S)-1-[(2S)-3-(1H-IMIDAZOL-4-YL)-2-{[(2S)-5-OXOPYRROLIDIN-2-YL]FORMAMIDO}PROPANOYL]PYRROLIDINE-2-CARBOXAMIDE;(2S)-1-[(2S)-3-(1H-IMIDAZOL-4-YL)-2-{[(2S)-5-OXOPYRROLIDIN-2-YL]FORMAMIDO}PROPANOYL]PYRROLIDINE-2-CARBOXAMIDE;PROTIRELIN [VANDF];PROTIRELIN [VANDF];DA-64226;DA-64226;TRH [MI];TRH [MI];117217-40-0;117217-40-0;GTPL2139;GTPL2139;EN300-27034140;EN300-27034140;Protirelin, European Pharmacopoeia (EP) Reference Standard;Protirelin, European Pharmacopoeia (EP) Reference Standard;Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-;Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-;L-PYROGLUTAMYL-L-HISTIDYL-L-PROLINE-AMIDE;L-PYROGLUTAMYL-L-HISTIDYL-L-PROLINE-AMIDE;Protireline;Protireline;(2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide;(2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide;C03958;C03958;GTPL3836;GTPL3836;Thyrotropin-releasing factor (pig);Thyrotropin-releasing factor (pig);L-Pyroglutamyl-L-histidyl-L-prolineamide;L-Pyroglutamyl-L-histidyl-L-prolinea... |
| 詳細(xì)描述： |
轉(zhuǎn)鐵蛋白是血漿中主要的鐵傳遞蛋白，為細(xì)胞分化和細(xì)胞代謝提供所需的鐵。研究發(fā)現(xiàn) 所有的細(xì)胞生長(zhǎng)都離不開(kāi)轉(zhuǎn)鐵蛋白。不但維持正常的細(xì)胞代謝依賴(lài)于以生物活性形態(tài)存在的 鐵，鐵還是一些酶的輔助因子，比如 RNA 聚合酶，DNA 合成酶。同時(shí)也是血紅蛋白的重要 組成部分。
轉(zhuǎn)鐵蛋白是血漿糖蛋白，從血漿中分離而來(lái)，牛轉(zhuǎn)鐵蛋白以?xún)煞N分子形態(tài)存在，分子量 分別為 74KD 和 78KD。每個(gè)轉(zhuǎn)鐵蛋白分子通過(guò) C 端和 N 端結(jié)構(gòu)位點(diǎn)可以結(jié)合兩分子鐵離子， 所以轉(zhuǎn)鐵蛋白以三種形態(tài)存在：脫鐵（不結(jié)合鐵離子），飽和鐵（結(jié)合兩分子鐵離子）和部 分飽和，在生理情況下，轉(zhuǎn)鐵蛋白分子僅有 1/3 被鐵飽和。
使用說(shuō)明： 轉(zhuǎn)鐵蛋白對(duì)于絕大部分細(xì)胞系在無(wú)血清培養(yǎng)基中生長(zhǎng)是必需的，研究表明飽和鐵形態(tài)的 轉(zhuǎn)鐵蛋白對(duì)于促進(jìn)細(xì)胞生長(zhǎng)是最有效的形態(tài)。對(duì)于雜交瘤，黏連細(xì)胞和懸浮細(xì)胞系，在細(xì)胞 培養(yǎng)過(guò)程中，應(yīng)保持培養(yǎng)基中轉(zhuǎn)鐵蛋白濃度在 0.5-100μ g/ml。針對(duì)不同的細(xì)胞系，需要選 擇最合適的濃度。
轉(zhuǎn)鐵蛋白凍干粉需要保存在冷藏狀態(tài)下，使用之前再溶解。一般用 PBS 或者其它合適 的溶劑在室溫下將轉(zhuǎn)鐵蛋白凍干粉溶解成儲(chǔ)液，濃度在 0.5-2.0mg/ml,然后用無(wú)菌濾膜進(jìn)行過(guò) 濾，濾液可在無(wú)菌條件下 2-8℃保存 30 天。
外觀： 凍干粉末
儲(chǔ)存條件： 2-8℃ |
滬公網(wǎng)安備31011402010658號(hào) 
